Quarterly report pursuant to Section 13 or 15(d)

INVESTMENT (Details Narrative)

v3.22.2.2
INVESTMENT (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Mar. 12, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Schedule of Equity Method Investments [Line Items]          
Aggregrate investment   $ 6,000,000   $ 6,000,000  
Equity investment   5,000,000   5,000,000  
Convertable note investment   $ 1,000,000   $ 1,000,000  
Iliad [Member] | Class C Units [Member]          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage not fully diluted   9.50%   9.50%  
Iliad [Member]          
Schedule of Equity Method Investments [Line Items]          
Aggregrate investment   $ 6,000,000   $ 6,000,000  
Equity investment   5,000,000   5,000,000  
Equity investment net loss   $ 355,000 $ 231,000 $ 788,000 $ 446,000
Iliad [Member] | Class C Units [Member]          
Schedule of Equity Method Investments [Line Items]          
Ownership percentage fully diluted       7.20%  
I Liad Biotechnologies L L C [Member]          
Schedule of Equity Method Investments [Line Items]          
Additional convertable note investment $ 1,000,000        
Maximum convertible debt offering $ 23,500,000        
Interest rate 6.00%        
Notes conversion, description The Notes are required to be converted into a Qualified Financing (minimum financing of $15 million) at the lesser of (i) 80% of the price paid per unit in such offering or (ii) a price based on an enterprise value of $176,000,000.        
Enterprise value $ 176,000,000